In This Article:
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Monogram Technologies Inc (NASDAQ:MGRM) received FDA clearance for their embossed total TKA system, marking a significant milestone in the company's history.
-
The company has a strong balance sheet with $13.3 million in cash and no traditional debt, providing financial stability.
-
Monogram Technologies Inc (NASDAQ:MGRM) has reduced its monthly cash burn rate from $1.1-$1.2 million to $0.8 million, reflecting improved cost management.
-
The company is set to initiate a groundbreaking multi-center clinical trial in India for autonomous saw-based robotic total knee surgeries.
-
Monogram Technologies Inc (NASDAQ:MGRM) is actively showcasing its system to key opinion leaders and preparing for additional placements, indicating strong future growth potential.
Negative Points
-
The company anticipates a slow and methodical initial rollout, which may delay immediate commercial traction.
-
Monogram Technologies Inc (NASDAQ:MGRM) faces significant competition from established players like Stryker, which holds a dominant market share.
-
The company requires additional capital to accelerate growth, indicating potential future funding needs.
-
There are still technical and regulatory hurdles to overcome in both the US and India, which could impact timelines.
-
The company's commercial success is heavily dependent on surgeon adoption and the ability to demonstrate the system's value proposition in real-world settings.
Q & A Highlights
Q: Can you provide more detail on the timelines for technical and regulatory hurdles in the US and India? A: Unidentified_3: We expect to perform live patient surgeries in India within 90 business days, and the clinical trial system is on its way to India. In the US, our first placement is underway, and we anticipate it will be a reality in the operating room by Q3 2025.
Q: How does Monogram plan to differentiate itself from Stryker's Mako system, particularly in terms of surgeon adoption? A: Unidentified_3: We aim to be competitive with Mako by focusing on accuracy, safety, and efficiency. Our system is designed to minimize surgeon fatigue and improve tensioning. We also have an AI-based preoperative pipeline for landmark identification, which we believe will be a small advantage over Mako.
Q: What feedback have you received from key opinion leaders (KOLs) regarding the Monogram system? A: Unidentified_3: Initially, feedback was that the system was interesting but slow. Over time, we've improved speed and accuracy, and now surgeons are impressed with our progress. Surgeons familiar with Mako find our workflow intuitive.